POINT Biopharma Global Inc. (NASDAQ:PNT) Given Consensus Recommendation of “Hold” by Brokerages
POINT Biopharma Global Inc. (NASDAQ:PNT – Get Free Report) has earned an average rating of “Hold” from the nine research firms that are presently covering the stock, Marketbeat Ratings reports. Nine research analysts have rated the stock with a hold recommendation. The average twelve-month target price among brokerages that have covered the stock in the […]
More Stories
No Evidence Medical Cannabis Alleviates Anxiety, Depression, or PTSD: Study
By Zachary Stieber There is no evidence medical cannabis works against anxiety, depression, or post-traumatic stress disorder, according to a...
National Medical School Accreditor Scrapping DEI Requirements
By Aaron Gifford The nation’s largest medical school accreditor is phasing out its guidance on diversity, equity, and inclusion (DEI),...
Burgum Says Trump Energy Policies Make US Less Vulnerable to Upheaval, the World Safer
By John Haughey HOUSTON—President Donald Trump’s policies boosting American energy production are proving prescient with ships and pipelines carrying oil,...
NASA Unveils Plan for First Nuclear-Powered Interplanetary Spacecraft
By T. J. Muscaro The first-ever nuclear-powered spacecraft built for interplanetary travel will set off on a mission to Mars...
Senators Weigh Plan to End DHS Shutdown
By Jackson Richman and Nathan Worcester WASHINGTON—Senate Republicans are closing in on a plan to end the impasse over funding...
The Latest News From Major Tech Companies
By Louis Navellier The big investment news last week was Nvidia’s developer conference, which is already helping to boost storage...